论文部分内容阅读
目的观察联合利福霉素在治疗合并胸腔积液大叶性肺炎患儿中的作用。方法 118例合并胸腔积液大叶性肺炎患儿随机分成治疗组(62例)和对照组(56例),治疗组采用舒普深(注射用头孢哌酮舒巴坦钠)抗感染治疗,同时联合应用利福霉素,对照组单独采用用舒普深抗感染治疗,观察两组病愈、好转及无效例数,并进行统计学分析。结果治疗组病愈及好转例数多于对照组,无效例数少于对照组,两组比较差异具有统计学意义(P<0.05)。结论联合应用利福霉素治疗合并胸腔积液大叶性肺炎患儿,可以通过扩大抗菌谱,加强抗感染,阻断炎症反应等作用机制,从而促进其肺部炎症及胸腔积液的吸收。
Objective To observe the role of rifamycin in the treatment of children with pleural effusion pneumonia. Methods One hundred and fourteen children with pleural effusion pneumonia were randomly divided into treatment group (n = 62) and control group (n = 56). Patients in the treatment group were treated with Shu Pushen (cefoperazone sulbactam sodium for injection) At the same time the combination of rifamycin, the control group alone with shuopu anti-infective treatment, the two groups were observed, recovered and invalid cases, and statistical analysis. Results The number of cases recovered and treated in the treatment group was more than that of the control group, and the number of invalid cases was less than that of the control group. The difference between the two groups was statistically significant (P <0.05). Conclusions The combined use of rifamycin in children with pleural effusion with lobar pneumonia can promote its lung inflammation and absorption of pleural effusion by expanding the antibacterial spectrum, strengthening the anti-infection and blocking the inflammatory reaction mechanism.